Henoch-Schönlein Purpura Management

Diagnostic Criteria

• The American Journal of Kidney Diseases recommends diagnosis based on finding palpable purpura plus at least one of the following, including renal involvement (hematuria and/or proteinuria) 1

Management Approach

Specific Organ System Management

Renal Disease Management

• For children with HSP nephritis and persistent proteinuria, the American Journal of Kidney Diseases and Kidney International recommend treatment with ACE inhibitors or ARBs 1, 2
• For children with persistent proteinuria >1 g/day per 1.73 m² after ACE inhibitor/ARB trial and GFR >50 ml/min per 1.73 m², a 6-month course of corticosteroid therapy is suggested by the American Journal of Kidney Diseases and Kidney International 1, 2
• For crescentic HSP with nephrotic syndrome and/or deteriorating kidney function, treatment with steroids and cyclophosphamide is recommended by the American Journal of Kidney Diseases and Kidney International 1, 2
• The American Journal of Kidney Diseases suggests that for adults with HSP nephritis, the treatment approach should be the same as in children 3, 4
• Kidney International recommends that prophylactic use of corticosteroids is not recommended to prevent HSP nephritis (strong evidence) 2

Special Considerations

• The American Journal of Kidney Diseases notes that when needed for severe nephritis, options include steroids combined with azathioprine, cyclosporine, tacrolimus, or mycophenolate mofetil/mycophenolic acid; cyclophosphamide is used less frequently due to side effects 3

Safety of Toradol in Henoch-Schönlein Purpura

Renal Considerations

• Ketorolac (Toradol) is an NSAID that can cause acute kidney injury, especially in patients with pre-existing renal impairment, according to the American Medical Association, as reported in JAMA Surgery 5
• Acetaminophen (paracetamol) is recommended as a safer first-line analgesic option for HSP patients, as suggested by JAMA Surgery 5

Pain Management Alternatives

• Prednisone may be used for acute, widespread flares of HSP, particularly when pain control is needed, as recommended by the American Academy of Dermatology 6

Management of Henoch-Schönlein Purpura (HSP) with Dietary Considerations

Specific Organ System Management

• For joint pain and cutaneous symptoms, oral prednisone at 1-2 mg/kg daily for two weeks may be beneficial, and colchicine (1 mg/day) may be considered for persistent purpura and pain, with treatment for at least six months 7

Dietary Considerations

• A low-antigen-content (LAC) diet may improve symptoms and laboratory abnormalities when strictly followed for 4-8 weeks, and can be considered as supportive treatment in all symptomatic patients 7
• The LAC diet can be used in conjunction with other treatments, such as colchicine, for chronic or persistent symptoms 7

Henoch-Schönlein Purpura Diagnosis and Management

Diagnostic Approach

• The American College of Radiology recommends that the diagnosis of Henoch-Schönlein purpura (HSP) can be made clinically when palpable purpura is present plus at least one of the following: renal involvement, arthralgia/arthritis, or abdominal pain, with a clinical triad of hematuria, purpuric lesions, and ankle pain being diagnostic of HSP 8, 9, 10
• Urinalysis with microscopy is essential to assess for glomerulonephritis and proteinuria, looking specifically for proteinuria, red blood cell casts, and dysmorphic red blood cells, which indicate glomerular involvement 8, 9, 10
• A basic metabolic panel, including BUN, serum creatinine, and complete blood count with platelets, should be performed to assess renal function and rule out thrombocytopenia 8, 9
• Blood pressure measurement is essential as hypertension may indicate more severe renal involvement 10

Imaging Considerations

• Renal ultrasound is the preferred initial imaging modality to assess kidney size and anatomy, particularly if renal biopsy is being considered for severe nephritis 8, 9

Monitoring Protocol

• Monitor for persistent hematuria and proteinuria, as these may indicate ongoing disease activity 11

Renal Disease Management in Henoch-Schönlein Purpura

Initial Treatment Approach

• The National Kidney Foundation recommends starting ACE inhibitor or ARB therapy for persistent significant proteinuria in patients with Henoch-Schönlein Purpura, even though evidence is extrapolated from IgA nephropathy rather than HSP-specific trials 12, 13
• The American Journal of Kidney Diseases suggests targeting proteinuria to <1 g/day/1.73 m² rather than attempting complete normalization, which increases medication side effects without proven benefit 12, 13

Treatment of Moderate to Severe Renal Involvement

• The Kidney Disease Outcomes Quality Initiative (KDOQI) commentary recommends reserving corticosteroid therapy for nephrotic syndrome (proteinuria >3.5 g/day) or nephritic syndrome that has not improved with ACE inhibitor/ARB therapy 12, 13
• The American Journal of Kidney Diseases suggests treating severe renal involvement (crescentic HSP with nephrotic syndrome and/or deteriorating kidney function) with high-dose intravenous methylprednisolone plus cyclophosphamide, following the same protocol as crescentic IgA nephropathy 12, 13

Adult HSP Nephritis

• The American Journal of Kidney Diseases recommends treating adults with HSP nephritis using the same approach as children, though adults have worse prognosis and higher risk of progression to end-stage renal disease 12, 13

Common Pitfalls to Avoid

• The National Kidney Foundation warns against starting corticosteroids too early for mild proteinuria without adequate trial of ACE inhibitor/ARB therapy, as this may increase side effects without proven benefit 12, 13
• The American Journal of Kidney Diseases advises against attempting to normalize proteinuria to <0.5 g/day/1.73 m², which increases side effects without proven benefit 12, 13

What Not to Do

• The American Journal of Kidney Diseases recommends not using corticosteroids prophylactically at HSP onset to prevent nephritis, as moderate quality evidence (Level 1B) shows no benefit in preventing nephritis or reducing risk of severe persistent nephritis 12, 13

Treatment of Henoch-Schönlein Purpura (HSP) Vasculitis

Critical Management Principles

• Failing to perform urinalysis at every clinical visit can lead to delayed detection of infection, renal relapse, or bladder complications, according to the Annals of the Rheumatic Diseases 14

Adult Henoch‑Schönlein Purpura: Evidence‑Based Management and Monitoring

Screening and Prognosis

• In adult patients, perform age‑ and sex‑appropriate screening for secondary causes and occult malignancy, because adults with HSP have a poorer prognosis and a higher risk of progression to end‑stage renal disease. 15

Therapeutic Recommendations

Prophylactic Steroid Use

• Prophylactic corticosteroids at disease onset do not prevent nephritis or reduce the risk of severe persistent nephritis; moderate‑quality evidence (Grade 1B) shows no benefit and exposes patients to unnecessary steroid toxicity. 15

Dietary Sodium Restriction

• Advise a dietary sodium limit of less than 2 g per day to support renal health in HSP patients. 16

Monitoring Protocol

• Monitor proteinuria and renal function for a minimum of 6 months, since the majority of nephritis manifests within 3 months after initial presentation. 15

All statements are derived from peer‑reviewed evidence cited above.